These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10719735)

  • 1. Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer.
    Zalcman G; Trédaniel J; Schlichtholz B; Urban T; Milleron B; Lubin R; Meignin V; Couderc LJ; Hirsch A; Soussi T
    Int J Cancer; 2000 Jan; 89(1):81-6. PubMed ID: 10719735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum anti-p53 antibodies in patients with lung cancer.
    Mack U; Ukena D; Montenarh M; Sybrecht GW
    Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.
    Rosenfeld MR; Malats N; Schramm L; Graus F; Cardenal F; Viñolas N; Rosell R; Torà M; Real FX; Posner JB; Dalmau J
    J Natl Cancer Inst; 1997 Mar; 89(5):381-5. PubMed ID: 9060960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
    Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
    Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation.
    Segawa Y; Takigawa N; Mandai K; Maeda Y; Takata I; Fujimoto N; Jinno K
    Lung Cancer; 1997 Mar; 16(2-3):229-38. PubMed ID: 9152954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
    Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
    Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
    Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
    Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The detection of quantitative serum p53 protein in lung cancer.
    Sen E; Gönüllü U; Akar N
    Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of serum p53 antibodies in lung cancer.
    Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L
    BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer.
    Oshita F; Kameda Y; Hamanaka N; Saito H; Yamada K; Noda K; Mitsuda A
    Am J Clin Oncol; 2004 Jun; 27(3):215-9. PubMed ID: 15170136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres.
    Jørgensen LG; Osterlind K; Genollá J; Gomm SA; Hernández JR; Johnson PW; Løber J; Splinter TA; Szturmowicz M
    Br J Cancer; 1996 Aug; 74(3):463-7. PubMed ID: 8695366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance.
    Jassem E; Bigda J; Dziadziuszko R; Schlichtholz B; Le Roux D; Grodzki T; Rzyman W; Konopa K; Poberezna M; Dobrzańska Z; Skokowski J; Soussi T; Jassem J
    Lung Cancer; 2001 Jan; 31(1):17-23. PubMed ID: 11162862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer.
    Salven P; Ruotsalainen T; Mattson K; Joensuu H
    Int J Cancer; 1998 Apr; 79(2):144-6. PubMed ID: 9583728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer.
    Paik KH; Park YH; Ryoo BY; Yang SH; Lee JC; Kim CH; Ki SS; Kim JM; Park MJ; Ahn HJ; Choi W; Chung JH
    J Korean Med Sci; 2006 Feb; 21(1):35-9. PubMed ID: 16479062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study.
    Segawa Y; Kageyama M; Suzuki S; Jinno K; Takigawa N; Fujimoto N; Hotta K; Eguchi K
    Br J Cancer; 1998 Sep; 78(5):667-72. PubMed ID: 9744508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome.
    Gemba K; Ueoka H; Kiura K; Tabata M; Harada M
    Lung Cancer; 2000 Jul; 29(1):23-31. PubMed ID: 10880844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
    Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
    Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.
    Graus F; Dalmou J; Reñé R; Tora M; Malats N; Verschuuren JJ; Cardenal F; Viñolas N; Garcia del Muro J; Vadell C; Mason WP; Rosell R; Posner JB; Real FX
    J Clin Oncol; 1997 Aug; 15(8):2866-72. PubMed ID: 9256130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors confounding evaluation of treatment effect in lung cancer.
    Osterlind K
    Lung Cancer; 1994 Mar; 10 Suppl 1():S97-103. PubMed ID: 8087532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.